Sitimagene Ceradenovec: A Gene-Based Drug for the Treatment of Operable High-Grade Glioma

Abstract

The field of gene therapy for malignant glioma has made important advances since the first gene transfer studies were performed 20 years ago. Multiple Phase I/II trials and two Phase III trials have been performed and have demonstrated the feasibility and safety of intratumoral vector delivery in the brain. Sitimagene ceradenovec is an adenoviral vector encoding the herpes simplex thymidine kinase gene, developed by Ark Therapeutics Group plc (UK and Finland) for the treatment of patients with operable high-grade glioma. In preclinical and Phase I/II clinical studies, sitimagene ceradenovec exhibited a significant increase in survival. Although the preliminary results of a Phase III clinical study demonstrated a significant positive effect of sitimagene ceradenovec treatment on time to reintervention or death when compared with standard care treatment (hazard ratio: 1.43; 95% CI: 1.06-1.93; p < 0.05), the European Committee for Medicinal Products for Human Use did not consider the data to provide sufficient evidence of clinical benefit. Further clinical evaluation, powered to demonstrate a benefit on a robust end point, is required. This article focuses on sitimagene ceradenovec and provides an overview of the developments in the field of gene therapy for malignant glioma.

Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up

“…6,7,29,31,33 Our updated study suggests that trials combining these strategies appear to be considerably superior to each monotherapy. The basis of CT clinical efficacy was the induction of an effective local and systemic antitumor response.…”

Gene-Directed Enzyme Prodrug Cancer Therapy

“…Although integration of viral genome into host cell genome ensures the continuous high expression of transgene, the chance of insertional mutagenesis and its unknown consequences has led to the design of replication-deficient vectors [105]. Although this design provides a level of safety, replication-deficient vectors were not very successful in in vivo studies because they cannot support a long-term gene expression [11,106,107]. To overcome this problem, replication-competent retroviruses (RCRs) were designed, but their inability to controlled spread is still of major concern [108].…”

“…Three clinical trials have been done to investigate the appropriate dose, safety, and efficacy of Cerepro [106,111,112]. An ongoing phase III study using Cerepro with 250 patients has shown promising results [107].…”

Gene therapy is a new area in medicine

“…Среди препаратов, предназначенных для GDEPT, можно выделить Sitimagene ceradenovec (Cerepro, «Ark Therapeutics Group Plc», Великобритания и Финляндия) на основе аденовирусного вектора со встроенным «суицидным» геном HSVtk. Этот препарат прошел I/II фазы клинических ис-пытаний (глиома), в которых показана безопасность внутриопу-холевой доставки вирусной тимидинкиназы в глиальные клетки, при этом отмечена стабилизации процесса у пациентов [30,31].…”